You are here: Industry Insights > Relmada

News List

Relmada Announces Outcome of FDA Meeting for Major Depressive Disorder Treatment americanpharmaceuticalreview
June 02, 2020
Relmada Therapeutics announced the completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its development program of REL-1017 (dextromethadone) for the adjunctive treatment of major depressive disorder (MDD) patients.
Relmada Completes Dosing of REL-1017 in Phase 2 of Treatment Resistant Depression Study americanpharmaceuticalreview
July 30, 2019
Relmada Therapeutics announced the last subject has completed dosing with REL-1017 (dextromethadone) in the company's double-blind, placebo-controlled Phase 2 clinical study evaluating the safety and efficacy of REL-1017 as ...
Relmada Provides Enrollment Update in REL-1017 Study americanpharmaceuticalreview
September 20, 2018
Relmada Therapeutics announces that since dosing the first subject on June 27, 2017, 25% of the planned subjects received treatment in its Phase 2 study of dextromethadone (REL-1017) in depression.